[Form 4] Protara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Protara Therapeutics CEO and President Jesse Shefferman reported new equity awards. On January 16, 2026, he received 87,000 shares of common stock at a price of $0 pursuant to restricted stock unit (RSU) awards, bringing his directly held common shares to 1,046,886.

He was also granted stock options covering 524,000 shares of common stock at an exercise price of $5.01 per share, with 524,000 derivative securities held directly after the grant. The RSUs vest in three equal annual installments on the first, second, and third anniversaries of January 16, 2026, contingent on his continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in equal monthly installments over the next three years, also subject to continued service, and expire on January 15, 2036.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shefferman Jesse

Role CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	524,000	$0.00	--
Grant/Award	Common Stock	87,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 524,000 shares (Direct); Common Stock — 1,046,886 shares (Direct)

Footnotes (1)

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shefferman Jesse

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		87,000(1)	A	$0	1,046,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.01	01/16/2026		A		524,000		(2)	01/15/2036	Common Stock	524,000	$0	524,000	D

Explanation of Responses:

1. The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

2. 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

	/s/ Jesse Shefferman	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TARA CEO Jesse Shefferman report?

On January 16, 2026, Jesse Shefferman reported receiving 87,000 shares of Protara Therapeutics (TARA) common stock through RSU awards and a stock option grant for 524,000 shares of common stock.

How many Protara Therapeutics (TARA) shares does the CEO own after this Form 4?

Following the reported transactions, Jesse Shefferman beneficially owns 1,046,886 shares of Protara Therapeutics common stock directly, as disclosed in the filing.

What are the vesting terms for the 87,000 RSUs reported by TARA's CEO?

The 87,000 RSUs vest in three equal one-third installments on the first, second, and third anniversaries of January 16, 2026, subject to Mr. Shefferman’s continuous service with Protara Therapeutics on each vesting date.

What are the key terms of the 524,000 stock options granted to the TARA CEO?

The 524,000 stock options have an exercise price of $5.01 per share. 25% of the underlying shares vest on the one-year anniversary of January 16, 2026, and 1/48th of the shares vest monthly thereafter over the following three years, with an expiration date of January 15, 2036, all subject to continued service.

Are the equity awards to the TARA CEO granted directly or through another entity?

The Form 4 indicates that both the common stock and stock options reported are held with direct (D) ownership by Jesse Shefferman, with no separate indirect ownership entity noted.

Does this TARA Form 4 show any sales of shares by the CEO?

No. The transactions reported for Jesse Shefferman on this Form 4 are coded "A" for acquisitions of RSU-related common stock and stock options; no dispositions or sales are listed in the excerpt.